ABN 202
Alternative Names: ABN-202Latest Information Update: 19 Jun 2024
At a glance
- Originator Abion
- Class Antineoplastics; Immunotherapies; Interferons; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants; Interferon beta replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 19 Apr 2023 Preclinical trials in Non-small cell lung cancer in South Korea (Parenteral)